Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.74 |
| ▸ | PDPK1 | O15530 | 4/20 | 0.74 |
| ▸ | NPC1 | O15118 | 3/20 | 0.74 |
| ▸ | POLB | P06746 | 1/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.74 |
| ▸ | MAPT | P10636 | 1/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.69 |
| ▸ | HPGD | P15428 | 2/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.69 |
| ▸ | GSK3B | P49841 | 1/20 | 0.51 |
| ▸ | PARP1 | P09874 | 5/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | CDC7 | O00311 | 1/20 | 0.42 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.42 |
| ▸ | MAP3K8 | P41279 | 4/20 | 0.39 |
| ▸ | STK17B | O94768 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4209817 | 0.87 | RAB9A (0.77) | RAB9APDPK1NPC1POLBSMN1; SMN2 | |
| SCHEMBL4213116 | 0.85 | PDPK1 (1.00) | RAB9APDPK1NPC1POLBSMN1; SMN2 | |
| SCHEMBL4208111 | 0.85 | RAB9A (0.74) | RAB9APDPK1NPC1POLBSMN1; SMN2 | |
| SCHEMBL17268781 | 0.85 | RAB9A (0.74) | RAB9APDPK1NPC1POLBSMN1; SMN2 | |
| SCHEMBL4726461 | 0.85 | RAB9A (0.78) | RAB9APDPK1NPC1POLBSMN1; SMN2 | |
| SCHEMBL3936506 | 0.85 | RAB9A (1.00) | RAB9APDPK1NPC1POLBSMN1; SMN2 | |
| SCHEMBL15703311 | 0.82 | NPC1 (1.00) | RAB9APDPK1NPC1POLBSMN1; SMN2 | |
| SCHEMBL4199830 | 0.79 | RAB9A (0.68) | RAB9APDPK1NPC1POLBSMN1; SMN2 | |
| SCHEMBL4208313 | 0.79 | RAB9A (0.77) | RAB9APDPK1NPC1POLBSMN1; SMN2 | |
| SCHEMBL5641135 | 0.78 | RAB9A (0.68) | RAB9APDPK1NPC1POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090030196-A1 | PIM KINASE INHIBITORS AS CANCER CHEMOTHERAPEUTICS | ABBOTT LABORATORIES (US) | 2009-01-29 | — | — | US | claimed |
| US-20090030196-A1 | PIM KINASE INHIBITORS AS CANCER CHEMOTHERAPEUTICS | ABBOTT LABORATORIES (US) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030196-A1 | PIM KINASE INHIBITORS AS CANCER CHEMOTHERAPEUTICS | PIM1, PIM3, PIM2 | RAB9A 3461/4885PDPK1 13/4885NPC1 2497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.